![Proposed Rule Puts Labs at Greater Risk of FCA Liability](https://www.g2intelligence.com/wp-content/uploads/2023/03/April23.NLR_.MedicareOverpaymentRules-iStock-1800x1250-1-1080x675.jpg)
Proposed Rule Puts Labs at Greater Risk of FCA Liability
CMS recently proposed a rule that would make the False Claims Act rule the standard for overpayments under the Affordable Care Act regulations.
CMS recently proposed a rule that would make the False Claims Act rule the standard for overpayments under the Affordable Care Act regulations.
Recently announced enforcement actions saw three big settlements, with two of those coming from medical centers.
Though last week’s cases didn’t involve labs or lab testing, most were FCA-related issues including inflated claims.
Last week saw the usual False Claims Act and kickback-related charges, with the biggest action involving urine drug testing.
In this month’s Labs in Court roundup, a medical device company and genetic testing company each win key victories.